| Catalog No. |
TD-HV571026 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Human |
| Isotype |
IgG1-kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
Q9NR61 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
REGN-421,SAR153192,CAS:1192578-27-0 |
| Background |
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |